HOPA and PTCE will host Oncology Pharmacists Connect on June 20-21 at Downright Austin, A Renaissance Hotel, in Austin, Texas. There will be 10+ live credit hours presented plus 4.5 HOPA-Curated BCOP CEs.
Get a full description of Oncology Pharmacists Connect and find hotel accommodations in the PTCE room block.
HOPA Presents 4.5 BCOP Credit Hours
HOPA has curated a half-day of in-person education that features some of the latest science and most sought-after BCOP learning available so far this year. This learning takes place on Friday, June 21, 2024, from 12:35-5:35 p.m. Central Time.
Register Here
Participate in all Four Courses immediately following Summer Oncology Pharmacists Connect from HOPA and PTCE.
Prevention and Treatment of Cancer-Associated Thrombosis (1.5 CEs)
Author: Andy Maldonado, PharmD, BCOP
Session Description: Cancer-associated venous thromboembolism (CAT) is a major cause of morbidity and mortality in patients with cancer. There have been several recent studies comparing direct oral anticoagulants (DOACs) with low-molecular weight heparin (LMWH) in the management of CAT. This session will discuss recent updates to guidelines for the prevention and management of CAT and will review data comparing the efficacy and safety of DOACs versus LMWH in the treatment of CAT.
Learning Objectives:
- Identify patients with cancer who may benefit from primary thromboprophylaxis
- Compare data for use of direct oral anticoagulants (DOACs) versus low-molecular weight heparin (LMWH) in the treatment of cancer-associated thrombosis (CAT)
- Select the most appropriate anticoagulant for treatment of CAT given patient-specific characteristics
- Discuss duration of treatment for CAT
Target Acquired: Implementation of an Oncology Precision Medicine Program (1 CE)
Authors: Mark Zangardi, PharmD, MS, BCOP and Elizabeth Hansen, PharmD, BCOP
Session Description: Cancer treatment is increasingly defined by biomarkers and genomic alterations, commonly known as precision medicine . Application of precision medicine is variable across institutions, with some employing formal programs, and others without dedicated infrastructure. Participants will evaluate their organization's approach to oncology precision medicine. The presenters will review the importance of precision medicine in oncology and strategies for implementation of a dedicated program, including justification for pharmacist involvement.
Learning Objectives:
- Describe the importance of biomarker and genomic testing in routine cancer care
- Define essential components, steps for creation, and best practices of a health system-based oncology precision medicine program
- Analyze various tools and training programs to support the practice of precision medicine
- Justify the inclusion of pharmacists in developing, launching, and maintaining a successful oncology precision medicine program
Updates in Acute Leukemia Treatment for Elderly Patients (1.5 CEs)
Author: Caitlin Rausch, PharmD, BCOP
Session Description: This session will focus on treating and optimizing drug therapy in elderly patients with acute leukemia. Treatment of elderly patients with acute leukemia poses a significant clinical challenge as their co-morbidities and/or decreased performance status places them at a higher risk of morbidity and mortality with standard intensive chemotherapies. Furthermore, disease features portending a poor prognosis are more frequent among elderly patients. Empiric dose reductions of intensive therapies decreases effectiveness thereby negatively impacting outcomes. Designing effective low-intensity therapies incorporating novel agents and utilizing evidence-based data is imperative in improving outcomes and mitigating toxicities when treating elderly patients with acute leukemia. The goal of this 1.5 hour session is to discuss the shift in treatment paradigm for elderly patients with acute leukemia with the incorporation of novel agents and low-intensity therapy. The session will discuss evidence based data of low-intensity therapies adapted for elderly patients in both acute myeloid leukemia and acute lymphoblastic leukemia and provide strategies for optimal management of adverse events. Goals of therapy and cost of care for this population will also be discussed. This session will provide fundamentals in designing therapies for elderly patients with acute leukemia while highlighting some of the challenges we face in taking care of this population in acute leukemia. Real-world cases with utilization of evidence-based data and ADE management/mitigation strategies will be presented to facilitate application of the subject.
Learning Objectives:
- Describe the natural history and past treatment paradigm of acute leukemias in elderly patients
- Summarize current advances and novel agents used in the treatment of elderly patients with acute leukemias
- Apply evidence-based principles to clinical scenarios of elderly patients with acute leukemia, including dose modifications and supportive care management
- Evaluate the clinical evidence and place in therapy of novel agents for elderly patients with ALL and AML including inotuzumab, blinatumomab, BCR::ABL1 tyrosine kinase inhibitors, venetoclax, IDH and FLT3 inhibitors
- Design a comprehensive treatment regimen for elderly patients with acute leukemia utilizing patient-specific factors and goals of therapy
Up to My Neck (In Head and Neck Cancer Updates) (1.0 CE)
Author: Christine Barrett, PharmD, BCOP
Session Description: Head and neck cancer is the seventh most common cancer worldwide, accounting for 1.5% of all cancer deaths in the United States. In patients with advanced disease, the overall prognosis is poor, and there is a need to better optimize treatment. This presentation will focus on data in the recurrent and metastatic setting, as well as ongoing studies in both early and advanced stage disease. Recently published data will be interpreted, including studies on chemo-immunotherapy in nasopharyngeal carcinoma. This presentation will provide guidance on how to tailor first-line therapy in patients with advanced disease. Lastly, we will discuss ongoing trials that are being conducted, which include the evaluation of immunotherapy in the perioperative setting, and novel therapy combinations.
Learning Objectives:
- Review current guidelines for the treatment of recurrent and metastatic head and neck cancers
- Interpret the latest data in recurrent and metastatic head and neck cancer
- Recommend appropriate treatment for recurrent and metastatic head and neck cancer based on patient- and disease-specific factors
- Discuss ongoing clinical trials for systemic therapy in head and neck cancer
Please note: Program content subject to change based on new data presented at ASCO Annual Meeting. All 4.5 BCOP/ACPE credits must be claimed in HOPA Learn by no later than Monday, August 5, 2024.
Credits & Cost
- Credit Type: BCOP
- Start Date: June 21, 2024
- Last Purchase Date: June 21, 2024
- Member Price: 150.00
- Non-Member Price: $195.00
- BCOP Credit Amount: 4.5
- Credit Claim Expiration Date: August 05, 2024